EW Edwards Lifesciences Corp

Price (delayed)

$81.64

Market cap

$49.66B

P/E Ratio

33.19

Dividend/share

N/A

EPS

$2.46

Enterprise value

$49.59B

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the SAPIEN transcatheter aortic heart valve made of ...

Highlights
The price to earnings (P/E) is 33% lower than the 5-year quarterly average of 49.6 and 14% lower than the last 4 quarters average of 38.4
EW's gross profit is up by 8% year-on-year
EW's quick ratio is down by 28% since the previous quarter and by 10% year-on-year
The equity has declined by 7% since the previous quarter

Key stats

What are the main financial stats of EW
Market
Shares outstanding
608.31M
Market cap
$49.66B
Enterprise value
$49.59B
Valuations
Price to earnings (P/E)
33.19
Price to book (P/B)
8.69
Price to sales (P/S)
9.39
EV/EBIT
27.75
EV/EBITDA
25.38
EV/Sales
9.21
Earnings
Revenue
$5.38B
EBIT
$1.79B
EBITDA
$1.95B
Free cash flow
$973.6M
Per share
EPS
$2.46
Free cash flow per share
$1.57
Book value per share
$9.39
Revenue per share
$8.7
TBVPS
$11.05
Balance sheet
Total assets
$8.29B
Total liabilities
$2.49B
Debt
$691.3M
Equity
$5.81B
Working capital
$2.07B
Liquidity
Debt to equity
0.12
Current ratio
3.03
Quick ratio
1.87
Net debt/EBITDA
-0.04
Margins
EBITDA margin
36.3%
Gross margin
79.9%
Net margin
28.3%
Operating margin
31.8%
Efficiency
Return on assets
18%
Return on equity
25.6%
Return on invested capital
31.7%
Return on capital employed
24.6%
Return on sales
33.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EW stock price

How has the Edwards Lifesciences stock price performed over time
Intraday
1.43%
1 week
2.81%
1 month
1.49%
1 year
-30.07%
YTD
9.42%
QTD
9.42%

Financial performance

How have Edwards Lifesciences's revenue and profit performed over time
Revenue
$5.38B
Gross profit
$4.3B
Operating income
$1.71B
Net income
$1.52B
Gross margin
79.9%
Net margin
28.3%
The operating income has grown by 9% YoY and by 6% from the previous quarter
EW's gross profit is up by 8% year-on-year
The company's operating margin rose by 6% YoY and by 5% QoQ
EW's gross margin is up by 5% year-on-year

Growth

What is Edwards Lifesciences's growth rate over time

Valuation

What is Edwards Lifesciences stock price valuation
P/E
33.19
P/B
8.69
P/S
9.39
EV/EBIT
27.75
EV/EBITDA
25.38
EV/Sales
9.21
The price to earnings (P/E) is 33% lower than the 5-year quarterly average of 49.6 and 14% lower than the last 4 quarters average of 38.4
The company's EPS rose by 5% QoQ and by 2.1% YoY
The stock's price to book (P/B) is 21% less than its 5-year quarterly average of 11.0 and 10% less than its last 4 quarters average of 9.7
The equity has declined by 7% since the previous quarter
The P/S is 14% below the 5-year quarterly average of 10.9 and 12% below the last 4 quarters average of 10.7
EW's revenue is up by 2.9% year-on-year

Efficiency

How efficient is Edwards Lifesciences business performance
Edwards Lifesciences's return on equity has decreased by 10% YoY but it has increased by 4.5% QoQ
The company's return on invested capital fell by 9% YoY but it rose by 5% QoQ
EW's return on assets is down by 6% year-on-year but it is up by 4.7% since the previous quarter
The company's return on sales rose by 4.1% QoQ

Dividends

What is EW's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EW.

Financial health

How did Edwards Lifesciences financials performed over time
EW's quick ratio is down by 28% since the previous quarter and by 10% year-on-year
The company's current ratio fell by 21% QoQ
The debt is 88% less than the equity
The company's debt to equity rose by 9% QoQ
The equity has declined by 7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.